GW&K Investment Management LLC trimmed its position in Catalent Inc (NYSE:CTLT) by 0.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,888,234 shares of the company’s stock after selling 5,769 shares during the quarter. Catalent makes up 1.4% of GW&K Investment Management LLC’s portfolio, making the stock its 3rd biggest position. GW&K Investment Management LLC’s holdings in Catalent were worth $86,009,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of CTLT. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in shares of Catalent during the 2nd quarter valued at about $145,000. Moneta Group Investment Advisors LLC lifted its holdings in shares of Catalent by 105.0% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after purchasing an additional 1,800 shares in the last quarter. CIBC Asset Management Inc bought a new position in shares of Catalent during the 3rd quarter valued at about $217,000. Hartford Investment Management Co. bought a new position in shares of Catalent during the 2nd quarter valued at about $220,000. Finally, Rehmann Capital Advisory Group lifted its holdings in shares of Catalent by 1,895.9% during the 2nd quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock valued at $222,000 after purchasing an additional 5,043 shares in the last quarter. Institutional investors own 92.08% of the company’s stock.
In other news, insider Barry Littlejohns sold 47,265 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $41.64, for a total transaction of $1,968,114.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Lance Miyamoto sold 6,525 shares of the company’s stock in a transaction that occurred on Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total value of $277,312.50. The disclosure for this sale can be found here. Insiders sold a total of 184,335 shares of company stock worth $8,161,727 in the last 90 days. Company insiders own 1.40% of the company’s stock.
NYSE CTLT opened at $37.51 on Monday. The company has a market capitalization of $5.45 billion, a price-to-earnings ratio of 23.59, a PEG ratio of 2.23 and a beta of 1.45. The company has a current ratio of 2.05, a quick ratio of 1.79 and a debt-to-equity ratio of 1.44. Catalent Inc has a 52 week low of $34.24 and a 52 week high of $47.87.
Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 6th. The company reported $0.28 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.04. The firm had revenue of $551.80 million for the quarter, compared to analysts’ expectations of $582.44 million. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.21 EPS. As a group, equities analysts expect that Catalent Inc will post 1.72 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/11/12/catalent-inc-ctlt-is-gwk-investment-management-llcs-3rd-largest-position.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: How is Preferred Stock Different from Common Stock?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.